Meeting
2015 Gastrointestinal Cancers Symposium
A phase 3 open-label, randomized, multicenter study of Imprime PGG in combination with cetuximab in patients with KRAS wild type metastatic colorectal cancer.
Authors
Richard Dale Huhn
Biothera, Eagan, MN
Richard Dale Huhn , Jamie Lowe , Michele Grady , Corina Candiani Taitt , Michele Anne Gargano , Ada H. Braun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Prevention, Diagnosis, and Screening
Clinical Trial Registration Number
NCT01309126
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr TPS787)
DOI
10.1200/jco.2015.33.3_suppl.tps787
Abstract #
TPS787
Poster Bd #
F25
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase 3 open-label, randomized, multicenter study of imprime PGG in combination with cetuximab in patients with KRAS wild type metastatic colorectal cancer.
First Author: Richard Dale Huhn
Poster
2021 Gastrointestinal Cancers Symposium
PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).
First Author: John H. Strickler
Poster
2022 ASCO Annual Meeting
NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status.
First Author: Samuel A. Jacobs
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase II single-arm study of palbociclib and cetuximab rechallenge in KRAS/NRAS/BRAF wild-type (KRAS WT) metastatic colorectal cancer (mCRC) patients (pts).
First Author: Jonathan D Sorah